Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973365 | 0.86 | EGFR (0.55) | EGFRERBB2MEN1KMT2AKAT6A | |
| SCHEMBL3977341 | 0.84 | CA1 (0.48) | EGFRERBB2PLA2G10PLA2G2A | |
| SCHEMBL3974012 | 0.84 | EGFR (0.46) | EGFRERBB2MEN1KMT2AKAT6A | |
| SCHEMBL3975403 | 0.81 | EGFR (0.69) | EGFRERBB2PLA2G10PLA2G2A | |
| SCHEMBL6851854 | 0.77 | GBA1 (0.54) | MEN1KMT2AKAT6AGBA1 | |
| SCHEMBL16739378 | 0.75 | MEN1 (0.55) | MEN1KMT2AKAT6AGBA1 | |
| SCHEMBL29489599 | 0.75 | MEN1 (0.55) | MEN1KMT2AKAT6AGBA1 | |
| SCHEMBL3975862 | 0.74 | PLA2G10 (0.53) | EGFRERBB2MEN1KMT2APLA2G10 | |
| SCHEMBL3972176 | 0.74 | EGFR (0.60) | EGFRERBB2 | |
| SCHEMBL3973201 | 0.74 | PTGER3 (0.47) | EGFRERBB2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569602-B2 | Furan derivatives as EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| EP-1673360-B1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-7417068-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-08-26 | — | — | US | disclosed |
| US-20050124676-A1 | EP4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124676-A1 | EP4 receptor antagonists | PTGER4, PTGER3, NR4A3 | EGFR 433/4885ERBB2 854/4885KCNA5 1033/4885 |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER3, NR4A3 | EGFR 433/4885ERBB2 854/4885KCNA5 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.